Alnylam Pharmaceuticals (ALNY) Gross Margin: 2009-2025
Historic Gross Margin for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Sep 2025 value amounting to 84.21%.
- Alnylam Pharmaceuticals' Gross Margin rose 58.00% to 84.21% in Q3 2025 from the same period last year, while for Sep 2025 it was 80.65%, marking a year-over-year decrease of 619.00%. This contributed to the annual value of 86.37% for FY2024, which is 104.00% up from last year.
- Per Alnylam Pharmaceuticals' latest filing, its Gross Margin stood at 84.21% for Q3 2025, which was up 3.14% from 81.64% recorded in Q2 2025.
- In the past 5 years, Alnylam Pharmaceuticals' Gross Margin registered a high of 89.80% during Q2 2024, and its lowest value of -133.94% during Q1 2025.
- For the 3-year period, Alnylam Pharmaceuticals' Gross Margin averaged around 64.86%, with its median value being 83.63% (2024).
- In the last 5 years, Alnylam Pharmaceuticals' Gross Margin soared by 1,344bps in 2024 and then plummeted by 22,290bps in 2025.
- Quarterly analysis of 5 years shows Alnylam Pharmaceuticals' Gross Margin stood at 86.99% in 2021, then slumped by 77bps to 86.22% in 2022, then plummeted by 259bps to 83.63% in 2023, then slumped by 94bps to 82.69% in 2024, then soared by 58bps to 84.21% in 2025.
- Its Gross Margin was 84.21% in Q3 2025, compared to 81.64% in Q2 2025 and -133.94% in Q1 2025.